Moderna Inc. ($MRNA) Stock Forecast: Down 6.4% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its development of mRNA-based vaccines, including the widely used COVID-19 vaccine.

Why is Moderna Inc. going down?

MRNA stock is down 6.4% on May 6, 2025 16:46

• Moderna experienced a drop in its stock price as reactions were negative towards a decrease in COVID-19 vaccine demand and setbacks in FDA approval for a flu/COVID-19 combo shot.
• The company surpassed earnings per share expectations, but concerns remain due to a focus on cost reduction and product portfolio expansion that did not fully alleviate worries about revenue dips and vaccine approval delays.
• Market fluctuations were possibly due to investors reassessing Moderna's future growth potential post-pandemic, resulting in stock sales driven by uncertainties surrounding upcoming revenue sources.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.

https://www.zacks.com/stock/news/2463177/moderna-sharpens-pipeline-focus-as-covid-19-vaccine-demand-ebbs-in-q1

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 - Moderna ( NASDAQ:MRNA )

Moderna Q1 EPS loss of $ ( 2.52 ) beat estimates, while revenue hit $108 million, topping forecast despite falling from last year. Spikevax sales reached $84 million in Q1; RSV vaccine mRESVIA saw $2 million in sales after recent international approvals.

https://www.benzinga.com/general/biotech/25/05/45145598/moderna-expands-cost-cutting-program-by-up-to-17-billion-fda-approval-for-flucovid-19-combo-shot-

Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.

https://www.zacks.com/stock/news/2460487/moderna-beats-on-q1-earnings-lags-on-revenues-focuses-on-cost-cuts

Moderna ( MRNA ) Reports Q1 Loss, Lags Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 13.70% and 14.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2459798/moderna-mrna-reports-q1-loss-lags-revenue-estimates

Trending Today

Pepe ($PEPE) Crypto Forecast: Up 46.0% Today

Injective ($INJ) Crypto Forecast: Up 17.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 15.4% Today

XRP ($XRP) Crypto Forecast: Up 8.4% Today

Ethereum ($ETH) Crypto Forecast: Up 23.5% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 11.1% Today

Solana ($SOL) Crypto Forecast: Up 9.0% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 10.2% Today

Sui ($SUI) Crypto Forecast: Up 10.0% Today

Copper ($COPPER) Commodity Forecast: Up 1.3% Today

Moderna Inc. Price History

01.04.2025 - MRNA Stock was down 5.1%

• Moderna (MRNA) reported a Q1 loss and lagged revenue estimates, leading to a bearish movement in the stock.
• The market reacted negatively to the earnings surprises, with the stock settling at a -0.75% change from its previous close.
• Despite some bullish options trends, the overall sentiment towards Moderna seems to have been impacted by the earnings report.
• Investors are likely cautious about the company's performance in the face of revenue challenges and may be awaiting pipeline updates for a potential turnaround in sentiment.

01.04.2025 - MRNA Stock was down 5.2%

• Moderna's stock closed at $27.19, down -0.75% from the previous close.
• The company reported mixed Q1 results, with a loss in EPS but revenue exceeding expectations. However, the delay in FDA approval for its Flu/COVID-19 combo shot until 2026 could have dampened investor sentiment.
• Moderna's focus on cost-cutting initiatives, despite beating earnings estimates, might have raised concerns about the company's future growth prospects.
• The market reaction could also be influenced by uncertainties surrounding the company's sales guidance for 2025 and questions about its performance in the upcoming quarters.

02.03.2025 - MRNA Stock was down 7.4%

• The decline in Moderna's stock price aligns with a broader trend in biotech stocks following the departure of a key FDA official, Peter Marks, over disagreements with the new HHS Secretary. This event has sparked apprehensions regarding regulatory hurdles and leadership stability in the biotech sector.
• Despite optimism evident in options trading, indicating investor expectations of positive outcomes, Moderna's overall market sentiment appears to have been overshadowed by concerns arising from the FDA official's resignation and the resultant regulatory ambiguity.
• Pfizer's recent endorsement for expanding the use of its RSV vaccine in the EU may have further compounded the downward pressure on Moderna's stock as investors evaluate competitive dynamics and potential market implications for Moderna's vaccine portfolio.
• A combination of regulatory uncertainties, market forces, and competitive landscape changes likely contributed to Moderna's bearish performance today, underscoring the vulnerability of biotech stocks to regulatory updates and industry trends.

21.03.2025 - MRNA Stock was up 5.1%

• Despite Moderna's stock dropping slightly at the closing of the latest trading day, the overall bullish movement could be attributed to positive market sentiment and investor confidence in the company's innovative mRNA technology.
• The US Advisory Panel's vote to expand recommendations for Pfizer, GSK's RSV vaccines for older adults below 60 years might have indirectly benefited Moderna as a fellow player in the pharmaceutical industry, leading to increased investor interest and a bullish market movement for MRNA.
• Investors may have interpreted the news as a sign of potential growth opportunities for Moderna in the vaccine market, contributing to the bullish movement in the stock price.

01.03.2025 - MRNA Stock was up 5.5%

• Moderna's stock experienced a strong bullish movement today, likely influenced by the following factors:
• The bullish stance taken by investors in Moderna's options market, with a majority opening trades with bullish expectations.
• The resignation of FDA official Peter Marks, which could potentially lead to changes in regulatory dynamics that investors perceive as favorable for Moderna.
• The overall positive sentiment towards biotech stocks despite the resignation, indicating confidence in the sector's future prospects.
• The uncertainty caused by the Trump administration's reported plans to reduce financial support for vaccine efforts, which could indirectly benefit Moderna as a leading vaccine developer.

26.02.2025 - MRNA Stock was down 6.1%

• The bearish movement in Moderna's stock could be attributed to the Trump administration's plans to cut financial support for vaccine alliance Gavi and scale back efforts to combat malaria.
• Investors may be concerned about the potential impact of reduced government support on Moderna's future vaccine development and sales.
• This development could be seen as a negative catalyst for Moderna's stock price, leading to a bearish market movement as investors react to the uncertainty surrounding the company's future prospects in vaccine development.

08.03.2025 - MRNA Stock was up 6.3%

• Moderna (MRNA) displayed a notable bullish movement recently.
• Approval of Vertex's Kaftrio for expanded use in Europe may have influenced investor sentiment in the biotech sector, including Moderna.
• The bearish outlook on Moderna options trading could be a short-term trend, possibly linked to profit-taking or market speculation.
• In general, positive developments in the biotech industry and potential profit-taking in Moderna options trading might have contributed to the recent bullish trend in Moderna's stock price.

06.04.2025 - MRNA Stock was down 6.4%

• Moderna experienced a drop in its stock price as reactions were negative towards a decrease in COVID-19 vaccine demand and setbacks in FDA approval for a flu/COVID-19 combo shot.
• The company surpassed earnings per share expectations, but concerns remain due to a focus on cost reduction and product portfolio expansion that did not fully alleviate worries about revenue dips and vaccine approval delays.
• Market fluctuations were possibly due to investors reassessing Moderna's future growth potential post-pandemic, resulting in stock sales driven by uncertainties surrounding upcoming revenue sources.

03.03.2025 - MRNA Stock was down 6.3%

• Moderna's stock experienced a bearish movement today.
• The bearish sentiment could be attributed to the resignation of a top FDA official, Peter Marks, which has caused uncertainty and concerns within the biotech industry.
• The bullish options trading on Moderna could be unrelated to the stock's movement today, as it might reflect a longer-term positive outlook on the company's prospects.
• Pfizer's recent approval for expanded use of its RSV vaccine in the EU may have also impacted market sentiment towards Moderna, leading to a shift in investor focus towards Pfizer in the short term.

10.03.2025 - MRNA Stock was down 8.5%

• The recent rise in bearish options activity on Moderna suggests a lack of confidence or negative sentiment among investors, potentially leading to a stock sell-off.
• This bearish trend might be driven by profit-taking actions following a period of strong performance or concerns about the company's future growth.
• The approval of Vertex's Kaftrio for expanded use in Europe may have shifted investor focus and funds away from Moderna, influencing the bearish market movement.
• In general, the uptick in bearish options activity and positive developments for a competitor in the biotech industry likely impacted Moderna's bearish performance today.

06.02.2025 - MRNA Stock was up 7.6%

• Company insiders purchasing shares valued at $6 million may indicate confidence in the company's future, leading to increased investor optimism and driving the stock price up.
• Unusual options activity, with a majority of investors entering trades with bullish expectations, added to positive sentiment around Moderna, contributing to the stock's strong upward movement.
• The blend of insider buying and bullish options activity likely triggered a domino effect, attracting more investors to participate in the upward trend and propelling MRNA stock to surge by 16% in a single day.

11.02.2025 - MRNA Stock was down 8.2%

• Moderna's stock experienced a notable decline today despite recent favorable developments, including the CEO's share purchase and company insiders buying shares totaling $6 million.
• The decrease in stock value could be linked to investors taking profits following a substantial rise in the stock price subsequent to the positive news.
• Various factors, such as industry-specific influences or broader market conditions, may have influenced market participants' decisions, resulting in the stock's downward trajectory.
• Traders are advised to attentively track both company-specific updates and general market trends to make well-informed trading choices with Moderna's stock.